Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wilderguide wilderguide Feb 29, 2012 8:36 PM Flag

    Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis

    $$$$$$$$

    I'm always missing something.

    I looked back just a little ways...
    ..and found this UCSF study dated mid-2011, regarding pancreatic islet cancer, co-authored by Don McDonald, MD. The same D.McDonald, MD that recently published on interactivity & synergy of response with VEGF & c-MET co-inhibition.

    http://cancerres.aacrjournals.org/content/early/2011/05/31/0008-5472.CAN-10-2527.abstract


    It may only be my hunch, but I feel these are the important MOA studies that will determine CABO's overall clinical prospect, and hence it's market value. I am coming to the conclusion that CABO's most unique characteristic seems to be it's continually repetitive ability to display broad preclinical response that actually does statistically translate to broad clinical benefit. How rare a bird is that? We're developing some great data. Keep yer flight harness at the ready.

    I see this slow-motion walkdown as a manipulation.
    GLTA

 
EXEL
14.89+0.15(+1.02%)Sep 23 4:00 PMEDT